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ABSTRACT 
Background: 
Eligibility criteria might explain differences in viral response to combined 
antiretroviral treatment (cART) between clinical trials and routine care setting. 
Our aim was to assess the effectiveness of cART and factors associated to 
therapeutic failure (TF) in real clinical conditions. 
 
Methods: 
A prospective cohort analysis including HIV-1 infected patients who started a 
cART between January 2004 and December 2009, at Vall d’Hebron Hospital. 
Effectiveness was evaluated as time to TF defined as the first of either virologic 
failure, treatment discontinuation whatever the reason other than switching, loss 
to follow-up, or death.  The Kaplan-Meier method was used to estimate time-to-
event distributions and Cox regression modelling to identify factors associated 
with TF. 
 
Results: 
We analyzed 232 patients; median CD4+ cell count was 229 cells/mm3 and 
median viral load 4.89 log10. Almost a third of patients was co-infected with HCV 
and/or HBV. Tenofovir plus lamivudine/emtricitabine (67%) was the commonest 
backbone, and efavirenz (77%) the preferred third drug. The proportion of 
patients with no TF at month 12, 24 and 36 was 82.9%, 78.5% and 76% 
respectively. TF occurred in 57 (24.6%) patients, mainly due to intolerance or 
toxicity. The risk of TF was higher in patients starting cART before 2006 and in 
those with a protease inhibitor based regimen.  
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Conclusions: 
After a median follow-up of 36.5 months, three-fourth of patients who started 
first-line cART remained free of TF. Treatment discontinuation stands as the 
leading cause of TF. 
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BACKGROUND 
Since the introduction of combined antiretroviral treatment (cART) a sustained 
efficacy improvement has been observed over time in randomized clinical trials 
(RCT). In recent RCT, by intent-to-treat analyses, 70% to over 80% of patients 
achieved viral suppression to <50 copies/mL at week 48 of treatment 1-5, and 
over 80% of patients who remain on treatment are able to maintain 
undetectable viral load for as long as three to seven years 6;7. However, 
eligibility criteria to enrol patients in RCT limits the extrapolation of results 
obtained to routine care setting 8. Scarce data is available comparing treatment 
response in RCT (efficacy) versus routine care (effectiveness). In a recent 
report, although differences did not reach statistical significance, the risk of viral 
failure at month 12 of treatment was 67% for routine care patients versus 73% 
in those enrolled in RCT, which supposed a 77% higher risk among patients in 
routine care (OR 1.77; 95% CI 0.98-3.23) 8. It is important to assess the 
effectiveness of cART in non selected patients and the durability of treatment 
response, the main goal of therapy. Furthermore, treatment failure is a good 
indicator of the quality of patient care and allows the identification of factors 
associated with treatment failure (TF) in clinical practice. 
In the present study, we assess the effectiveness of cART in real clinical 
conditions and try to identify which factors are associated with treatment 
outcome. A better understanding of the reasons leading to TF might be useful to 
improve long-term viral response to the first-line of cART. 
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METHODS 
Study Design and Patients: 
A cohort analysis including all consecutive HIV-1 infected patients who started a 
combined antiretroviral regimen (cART), for the first time between January 2004 
and December 2009 at Vall d’Hebron Hospital in Barcelona.  
Data was prospectively collected in an electronic-stored case record form, 
specifically developed for the management of the cohort data (ACyH). In this 
application demographic data; HIV risk factors; Centers of Disease Control and 
Prevention (CDC) stage according to 1993 definitions; initiation and stopping 
data of every single drug used; HIV-1 treatment initiation date; specific 
antiretroviral regimens used; the date and  the reasons for treatment change; 
causes of death, CD4 cell counts, plasma HIV-RNA levels as evaluated by the 
NASBA method Nuclisens EasyQ HIV-1 (Biomerieux®, Marcy l’Etoile, France); 
lower limit of detection changed over time: from 80 to 50 copies/mL during 2004 
and since then until study closure, 50 copies/ml, blood cell counts and blood 
chemistry test data is recorded at each patient visit. In our cohort, patients are 
periodically evaluated 1 to 3 months following the initiation of ART and then 
every 3 to 6 months. Adherence was evaluated by self-reported direct 
questioning and recorded as yes or no. 
A nurse-coordinated programme to strengthen patient’s adherence, including 
close follow-up of patients at higher risk for poor adherence (mental 
disturbances, drug abuse, etc) as well as measures to engage patient in care 
(i.e. patients missing a laboratory or clinical appointment are contacted by 
telephone call) was implemented in our Unit at the beginning of study period.  
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Resistance testing was systematically performed at baseline since January 
2007, following guidelines advice, and in case of viral failure, using the Virco-
TYPE HIV1 test (Virco BVBA, Mechelen, Belgium) from 2004-2006 and 
thereafter the TRUGENE HIV-1 genotiping Kit (Siemens Healthcare 
Diagnostics, Tarrytown NY, USA). Drug resistance-associated mutations 
(RAMs) were considered as defined by the International AIDS Society–USA 
guidelines 9. 
Effectiveness of treatment was evaluated as time to treatment failure (TF), 
using a modified intent-to treat (ITT) analysis that considered as TF any of the 
following events: virologic failure; treatment change or discontinuation whatever 
the reason other than switching; loss to follow-up or death. Patients who 
changed therapy because of simplicity aim or concerns about long-term toxicity 
had data censored at the switching time. Virologic failure was defined as never 
achieving a plasma viral load <200 copies/mL or having a viral load >200 
copies/mL after treatment week 24 in two consecutive determinations 10. For 
this analysis, time was 0 days for patients never achieving a plasma viral load 
<200 copies/mL. An additional on-treatment (OT) approach was performed as a 
sensitivity analysis of efficacy, considering virologic failure as the only imputable 
cause of TF. Causes of treatment failure; rate of patients with < 50 copies/ml at 
weeks 48 and 96 of treatment with the first cART regimen, and the rate of 
patients with < 50 copies/ml at the time of administrative study closure in June 
2011, irrespective of the number of cART regimen used, were included as 
secondary endpoints.  
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Patients’ follow-up was right-censored at the last available data regardless of 
the efficacy end point. Informed consent was obtained from every patient, 
before including all the information into our data base. 
 
Statistical analysis: 
Categorical variables were described as number (proportion) and continuous 
variables as median (IQR, interquartile range) at least otherwise specified. 
Student’s-T test for paired data was used for related quantitative variables and 
χ 2 test or McNemar test to compare categorical variables. 
Distribution of the time to treatment failure was estimated using the Kaplan–
Meier method. Predictors of TF were identified by Cox regression analysis, 
using a step-forward selection method. Variables with a P value  0.1 were 
retained in the regression equation. Relative risks are expressed as hazard 
ratios and 95% confidence intervals 
SPSS software for Windows (Version 15.0; SPSS, Chicago, IL) was used for 
statistical analyses. 
 
RESULTS 
Demographics and baseline characteristics of the 232 patients evaluated are 
summarized in Table 1. Median CD4+ cell count was 229 cells/mm3, 35% of 
patients had an advanced infection (CD4+ <200 cells/mm3) and 14.7% had a 
previously AIDS-defining event; median HIV RNA was 4.89 log10 and 43% of 
patients had >5 log10 at treatment start.  
Regarding the initial cART regimen, tenofovir (TDF) plus lamivudine/ 
emtricitabine (3TC/FTC) (67%) or abacavir (ABC) plus 3TC (15%) were the 
most common backbones (Table 2). Concerning the third drug, a NNRTI was 
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selected in 191 subjects (82.3%), mainly efavirenz (EFV) (n=179; 77.2%), as 
compared to 39 (16.8%) subjects who started a PI-containing regimen. Patients 
starting a PI-based regimen had a lower CD4 cell count, 187 cell/mm³, as 
compared to those starting with a NNRTI, 244 cell/mm³ (P=0.024). 
A triple NRTI combination was used in only 2 (0.9%) patients (Table 2).  
 
Treatment outcome: 
After a median follow-up of 36.5 months (IQR, 24.8-50.2), the cumulative 
proportion of patients remaining free of therapeutic failure was 76% (95% CI, 
70.3-81.7). Corresponding data at treatment month 12, 24 of treatment were 
82.9% (95% CI, 78-87.8) and 78.5% (95% CI, 73-84), respectively (Figure 1). 
Corresponding figures by on treatment analysis were 97% (95%CI, 94.6-99.3), 
95.3% (95%CI, 92.4- 98.2) and 93.7% (95%CI, 90.0-97.4) at month 12, 24 and 
36 of treatment, respectively. Treatment failure was observed in 57 (24.6%) 
patients, mainly due to intolerance or toxicity (13%) (Table 3). True virological 
failure was observed in 13 (5.6%) patients and occurred at median treatment 
time of 7.0 months (95%CI, 2.1-14.8).  
Starting cART in 2004-2005 vs. starting in 2006-2009, co-infection with HCV 
and/or HBV and starting a PI-based regimen were associated with a higher 
likelihood of therapeutic failure by univariate Cox’s regression analysis. On the 
other hand, demographic data, risk factor for HIV acquisition or pre-treatment 
availability of genotypic resistance test were not associated to treatment 
outcome. In a multivariate model, starting cART before 2006 and using a PI-
based regimen, were independently associated with a higher risk of TF. 
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Furthermore, a trend for a higher risk for TF was observed among patients 
coinfected with HVC and/or HBV  (Table 4). 
A significant mean increase in CD4+ cell count, 209 cells/mm³ (95%CI, 186-
232) was observed at week 48 of treatment.  At the end of follow-up the number 
of patients with CD4 above 350 cells/mm³ (n=189; 81.5%) significantly 
increased as compared to baseline (n=23; 9.9%) (p<0.001). No baseline 
variable, including demographic data, starting a PI-based vs. NNRTI-based 
regimen or HCV and/or HBV status, was significantly associated with CD4+ cell 
counts change. 
At the end of follow-up, considering missing data as treatment failure and 
regardless of the primary efficacy end point and the number of cART regimens 
used, 208 (90%) out of 232 patients had HIV RNA < 50 cop/ml. 
 
Emergence of drug resistance: 
A genotypic resistance test was performed in 9 of the 13 patients who 
experienced virological failure. Overall, the emergence of resistance-associated 
mutations (RAMs) occurred in 1 of 39 patients (25.6%) who started a PI-based 
regimen as compared to 5 of 191 patients (26.2%) on a NNRTI-based regimen 
(risk ratio= 0.98; 95%CI, 0.12-8.15). 
 
Tolerance and safety: 
Median duration of first line regimen was 29.0 months (IQR, 13.5-40.3). 
Intolerance or toxicity (12.9%), followed by switching (8.2%), were the main 
causes of treatment change or discontinuation of the initial antiretroviral 
regimen. (Table 3) 
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Main adverse events leading to therapeutic change were EFV-associated 
neurological toxicity and skin rash (Table 3). There were no grade 3-4 adverse 
events and only 2 patients (0.86%) presented hypersensitivity reaction to ABC. 
During the study period, 69 (29.7%) and 20 (8.6%) patients received 2 and  3 
different ART regimens, respectively. Main causes for change of the second-
line cART were: intolerance/toxicity (10 patients), switch (7 cases), virologic 
failure (2 cases) and pregnancy (1 patient). Eleven (4.7%) patients were lost to 
follow-up. Overall, 4 (1.7%) patients died, 3 of them under the initial ART 
regimen. Causes of death were, each one, primary cerebral lymphoma, 
Kaposi’s Sarcoma and laryngeal and lung neoplasias. 
 
DISCUSSION 
The effectiveness of currently used first-line cART regimens have increased 
substantially, greatly reducing the likelihood of initial regimen failure in 
conditions of clinical practice 11. In our study, over three-fourth of patients who 
started cART from 2004 to 2009 remained free of therapeutic failure to the first-
line regimen, after a median follow-up of 36.5 months. The effectiveness of 
cART in our population is similar to efficacy data reported from recently 
conducted RCT. Indeed, considering the overall population, irrespective of 
therapeutic changes for whichever reason (30% and 9% of patients received 2 
and 3 different regimens, respectively) almost 90% of patients who started 
cART in our cohort had viral suppression to less than 50 copies/mL at the end 
of follow up.  
Despite advances in antiretroviral treatment, as reflected by the excellent 
treatment outcome of our cohort, some patients do not respond optimally to 
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first-line therapy and a variety of reasons account for TF. In our study, the risk 
of TF was higher among patients starting cART before 2006 and those who 
received a PI-based regimen. Furthermore, a trend for a worse treatment 
outcome was observed among HCV and/or HVB co-infected patients. Poor 
tolerance to PI/r and poor tolerated or less convenient regimens formerly used 
in our cohort, which might be particularly relevant in co-infected patients12, are 
the most likely mechanisms resulting in TF among these patients.  
In agreement with previous studies 13-16, in our cohort treatment discontinuation 
was the main cause for regimen failure.  
The improvement of the toxicity profile of currently used NRTI as compared to 
thymidine-analogues and the better convenience of fixed-drug combinations, by 
improving tolerance and adherence, contributes to explain the high efficacy 
rates observed with contemporary used regimens both in RCT 5;17-19 and cohort 
studies 20;21 In keeping with these data, in the present study, TDF plus 
3TC/FTC was the most used NRTI combination (67%) followed by ABC plus 
3TC (15%), which represents an excellent backbone option in patients who test 
negative for HLA-B*5701 22, although a higher rate of viral failure may occur in 
patients with high pre-treatment viral load >100.000 cop/ml 5. Conversely, few 
patients (8.1%) started a thymidine-analogue containing regimen or a ddI-
including regimen. 
Furthermore, during the study, the thymidine-analogue was discontinued 
because toxicity or intolerance (n=4) or was proactively switched to a more 
convenient or less toxic NRTI (n=18). Early switch in order to minimize the risk 
of side effects and long-term toxicity or to improve convenience may be useful 
to support adherence and to increase long-term viral suppression 6;18 
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As a third drug, EFV was preferentially used in 77% of patients, which could 
contribute to explain the high rate of therapeutic success. EFV is a well 
tolerated, convenient and potent drug that has demonstrated a durable viral 
suppression in large RCT 18;23. Furthermore, EFV-based regimens have never 
been found to be inferior to any other third-drug strategy, triple NRTI 24;25; other 
NNRTI 26-28; PI-based regimens 29;30 or new viral target drugs such as raltegravir 
31
 or maraviroc 32. Nevirapine, may be a valid alternative to EFV 26;33, mainly in 
pregnancy or when neurologic toxicity might be a concern 22. In these events, 
CD4+ cell counts restrictions must be considered to minimize the risk of 
hypersensitivity to NEV 34;35. 
In contrast with data from a large multicentre European unselected cohort 36, 
high viral load or low pre-treatment CD4 cells counts were not associated with a 
higher risk of virologic failure in our study. In fact, none of the variables was 
independently associated with treatment outcome, which could be in relation 
with the large number of patients who started a TDF plus 3TC/FTC and EFV 
regimen 37. 
The incidence of high-level drug resistance has fallen over time following the 
introduction of cART for first-line therapy. In the EuroSIDA cohort, the incidence 
of triple-class failure over 5 years among patients who started a 3-drug HAART 
was 4.8% compared with 15.5% for patients who started on NRTI monotherapy 
or dual NRTI therapy before receiving HAART regiments 38. In our study, only 
13 patients (5.6%) experienced true virologic failure, and no differences were 
seen in the number of patients who developed RAMs between PIs and NNRTI-
based regimens, probably because of the small size of the cohort.  
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Some limitations of this study are to be mentioned. First of all, because the 
limited cohort sample size we are not able to confidently compare the 
effectiveness and the risk of drug resistance at viral failure between NNRTI and 
PI-based regimens; the differences in effectiveness among different PIs or 
different backbone combinations. In addition, very few patients received 
atazanavir and no patient was on darunavir during the study period, considered 
to be a preferred PI for naïve patients in current treatment guidelines 10;22.  
Also, genotypic resistance test at baseline was only available in 34.5% of 
patients (n=80), which could have a negative impact on patients starting a 
NNRTI-based regimen. However, treatment outcome was not associated with 
pre-treatment genotype assessment. Additionally, the number of patients who 
could be analyzed for genotype at viral failure was low. Finally, our data 
provides from a single centre and extrapolation to different populations should 
be cautiously made. An analysis of multisite cohort collaborations may be useful 
to evaluate this point. Nevertheless, demographic and clinical characteristics of 
patients at baseline are similar to that reported in other studies conducted in 
Spain 39 and the South of Europe 40.  
In summary, after a median follow-up of three years, three-fourth of patients 
who started a cART remained free of therapeutic failure. Treatment 
discontinuations because of intolerance/side effects or lost to follow up stands 
as the leading cause of therapeutic failure, which strengthens the importance of 
strategies addressed to optimize patient’s compliance. Simplicity and better 
toxicity profile of newer regimens, as well as additional measures to retain 
patients in care contribute to improve adherence and to achieve long-term 
virologic suppression in routine clinical setting, as suggested by the high 
16 
proportion of patients, 90%, who achieved viral suppression to less than 50 
copies/ml at the end of follow-up. 
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Table 1. Baseline characteristics of 232 patients analyzed 
 
Variable Value 
Age, years (IQR) 33.5 (28-41.8) 
Sex male, n (%) 175 (75.4%) 
Ethnic origin, n (%) 
White 
Hispanic 
Asian 
African 
 
168 (72.4%) 
44 (19%) 
3 (1.3%) 
17 (7.3%) 
Risk factor for HIV acquisition, n (%) 
Heterosexual 
Homosexual/bisexual 
IDU 
Other/Unknown 
 
101 (43.5%) 
89 (38.4%) 
35 (15.1%) 
7 (3%) 
HCV-coinfection, n (%) 59 (25.4%) 
HBV-coinfection, n (%) 13 (5.6%) 
Time since HIV diagnosis, months (IQR) 14.6 (3.1-34.8) 
Starting HAART year, n (%) 
2004-2005 
2006-2007 
2008-2009 
 
51 (22%) 
82 (35.3%) 
99 (42.6%) 
CD4 cell count at HAART initiation, 
median cell/mm³ (IQR) 
< 50, n (%) 
50-199 
200-349 
 350 
 
229 (160-289) 
21 (9.1%) 
60 (25.9%) 
128 (55.2%) 
23 (9.9%) 
Viral load (log10), median (IQR) 
> 100.000 cop/ml, n (%) 
4.89 (4.34-5.38) 
100 (43.1%) 
 
 
Table 1 footnotes 
IDU, intravenous drug user; HCV, hepatitis C virus; HBV, hepatitis B virus; 
HAART, high activity antiretroviral treatment 
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Table 2. Antiretroviral combinations used as a first-line regimen.  
 
Backbone Third drug-based cART Overall 
 Efavirenz Nevirapina Lopinavir/r Atazanavir/r Fosamprenavir/r Saquinavir/r  
TDF+FTC/3TC 132 (56.9%) 3 (1.3%) 7 (3%) 5 (2.1%) 4 (1.7%) 4 (1.7%) 155 (66.8%) 
ABC+3TC 22 (9.5%) 2 (0.8%) 1 (0.4%) 4 (1.7%) 4 (1.7%) 1 (0.4%) 34 (14.7%) 
AZT+3TC 7 (3%) 5 (2.1%) 3 (1.3%) - 1 (0.4%) - 16 (6.8%) 
ddI+3TC 15 (6.5%) 2 (0.8%) 1 (0.4%) 3 (1.3%) - 1 (0.4%) 22 (9.5%) 
d4T+3TC 3 (1.3%) - - - - - 3 (1.3%) 
Overall 179 (77.2%) 12 (5.2%) 12 (5.2%) 12 (5.2%) 9 (3.8%) 6 (2.5%) 230 (99.1%)1 
 
Table 2 footnotes 
1. Two additional patients (0.9%) started a regimen based on AZT plus 3TC and 
ABC 
ABC, abacavir; AZT, zidovudine; cART: combined antiretroviral treatment ; ddI. 
didanosine; d4T. Stavudine; FTC, Emtricitabine;  IDU, intravenous drug user; 
3TC, lamivudine; R, ritonavir-boosted; TDF, tenofovir 
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Table 3. Causes of discontinuation of the initial antiretroviral regimen  
 
 
Causes Value (%) 
Overall 83 (35.8) 
Switch 19 (8.2) 
Pregnancy 6 (2.6) 
Drug-drug interaction 1 (0.4) 
Therapeutic failure 
Any 57 (24.6) 
Intolerance/Side effects 30 (12.9) 
Neurological 
Hepatotoxicity 
Nefrotoxicity 
Gastrointestinal intolerance 
Skin rash 
Metabolic disorder 
Anemia 
11 (4.7) 
1 (<1) 
2 (<1) 
2 (<1) 
9 (3.9) 
1 (<1) 
4 (1.7) 
     Virological failure 13 (5.6) 
     Lost to follow up 11 (4.7) 
     Death  3  (1.3) 
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Table 4. Variables associated with treatment failure as assessed by Cox 
proportional hazards regression analysis  
  
 HR (95%CI) P HR 95%CI 1 Pa 
Sex Male vs. female 0.709 (0.414-1.320) 0.307   
Age >40 years  vs. <40 years 1.25 (.733-2.125) 0.414   
IDU vs. other transmission group 1.23 (0.640-2.38) 0.540   
cART starting year 
2004-2005 vs. 2006-2009 1.860 (1.066-3.247) 0.029 1.807 (1.028-3.176) 0.040 
HCV and/or HBV-coinfection vs. 
HIV monoinfection 1.976 (1.174-3.328) 0.010 1.608 (0.924-2.797) 0.093 
CD4+ cell count <200 /mm3  vs. 
>200/mm³ 1.342 (0.782-2.302  0.285   
HIV RNA >100.000 cop/ml  vs. 
<100.000 cop/ml 0.832 (0.489-1.413) 0.496   
TDF + 3TC/FTC backbone 0.613 (0.362-1.037) 0.068   
ABC + 3TC backbone 1.290 (0.630-2.650) 0.481   
PI vs. NNRTI-based starting 
regimen 2.118 (1.187-3.779) 0.011 1.893 (0.1029-3.485) 0.040 
 
 
Table 4 footnotes 
  
1. A Cox regression analysis, using a step-forward selection method, was 
performed to indentify variables associated to treatment outcome. Variables 
with a P value  0.1 are retained in the regression equation. Relative risks are 
expressed as hazard ratios (HR) and 95% confidence intervals (CI)  
 
ABC, abacavir; AZT, zidovudine; cART: combined antiretroviral treatment; ddI. 
didanosine; d4T. Stavudine; FTC, Emtricitabine;  IDU, intravenous drug user; 
3TC, lamivudine; NNRTI, non-nucleosida reverse transcriptase inhibitor; R, 
ritonavir-boosted; PI, protease inhibitor; TDF, tenofovir 
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Figure 1. Cumulative percentage of patients remaining free of therapeutic failure 
to the first-line regimen 
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